Mariko Siyue Koh

Mariko Siyue Koh

Auto-generated profile, based on publicly available information

Mariko Siyue Koh

Singapore General Hospital

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2018 in Respirology
Verified
Journal Article
Closed access
PDF file
VMVanessa M McDonald
Vanessa M McDonald
SHSarah A. Hiles
Sarah A. Hiles
KGKrystelle Godbout
Krystelle Godbout
EHErin S. Harvey
Erin S. Harvey
GMGuy Marks
Guy Marks
PGpeter gibson
peter gibson

1 October 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
LLLuis Pérez Pérez de Llano
Luis Pérez Pérez de Llano
GSGhislaine Scelo
Ghislaine Scelo
TTTrung N. Tran
Trung N. Tran
TLTham T. Le
Tham T. Le
MFMalin Fagerås
Malin Fagerås
DPDavid B. Price
David B. Price
Rationale: There is no consensus on criteria to include in an asthma remission definition in real life. Factors associated with achieving remission after biologic initiation remain poorly understood. Objectives: To quantify the proportion of adults with severe asthma achieving multidomain-defined remission after biologic initiation and identify prebiologic characteristics associated with achieving remission that may be used to predict it. Methods: This was a longitudinal cohort study using data from 23 countries from the International Severe Asthma Registry. Four asthma outcome domains were assessed in the 1 year before and after biologic initiation. A priori–defined remission cutoffs were: 0 exacerbations/yr, no long-term oral corticosteroid (LTOCS), partly/well-controlled asthma, and percent predicted FEV1 ⩾ 80%. Remission was defined using two (exacerbations + LTOCS), three (+control or +lung function), and four of these domains. The association between prebiologic characteristics and postbiologic remission was assessed by multivariable analysis. Measurements and Main Results: A total of 50.2%, 33.5%, 25.8%, and 20.3% of patients met criteria for two-, three- (+control), three- (+lung function), and four-domain remission, respectively. The odds of achieving four-domain remission decreased by 15% for every additional 10 years of asthma duration (odds ratio, 0.85; 95% confidence interval, 0.73–1.00). The odds of remission increased in those with fewer exacerbations per year, lower LTOCS daily dose, better control, and better lung function before biologic initiation. Conclusions: One in five patients achieved four-domain remission within 1 year of biologic initiation. Patients with less severe impairment and shorter asthma duration at initiation had a greater chance of achieving remission after biologic treatment, indicating that biologic treatment should not be delayed if remission is the goal.

7 June 2018 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MAMicheál Mac Aogáin
Micheál Mac Aogáin
RCRavishankar Chandrasekaran
Ravishankar Chandrasekaran
ALAlbert Yick Hou Lim
Albert Yick Hou Lim
TLTeck Boon Low
Teck Boon Low
GTGan Liang Tan
Gan Liang Tan
SCSanjay Haresh Chotirmall
Sanjay Haresh Chotirmall
Understanding the composition and clinical importance of the fungal mycobiome was recently identified as a key topic in a “research priorities” consensus statement for bronchiectasis.Patients were recruited as part of the CAMEB study: an international multicentre cross-sectional Cohort of Asian and Matched European Bronchiectasis patients. The mycobiome was determined in 238 patients by targeted amplicon shotgun sequencing of the 18S–28S rRNA internally transcribed spacer regions ITS1 and ITS2. Specific quantitative PCR for detection of and conidial quantification for a range of airwayAspergillusspecies was performed. Sputum galactomannan,Aspergillusspecific IgE, IgG and TARC (thymus and activation regulated chemokine) levels were measured systemically and associated to clinical outcomes.The bronchiectasis mycobiome is distinct and characterised by specific fungal genera, includingAspergillus,CryptococcusandClavispora.Aspergillus fumigatus(in Singapore/Kuala Lumpur) andAspergillus terreus(in Dundee) dominated profiles, the latter associating with exacerbations. High frequencies ofAspergillus-associated disease including sensitisation and allergic bronchopulmonary aspergillosis were detected. Each revealed distinct mycobiome profiles, and associated with more severe disease, poorer pulmonary function and increased exacerbations.The pulmonary mycobiome is of clinical relevance in bronchiectasis. Screening forAspergillus-associated disease should be considered even in apparently stable patients.

5 June 2018 in Allergy
Verified
Journal Article
Closed access
PDF file
AYAnthony Ca Yii
Anthony Ca Yii
TTTunn‐Ren Tay
Tunn‐Ren Tay
XCXue Ning Choo
Xue Ning Choo
MKMariko Sy Koh
Mariko Sy Koh
ATAugustine Kh Tee
Augustine Kh Tee
De Yun WangDe Yun Wang
De Yun Wang

27 April 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
PTPei Yee Tiew
Pei Yee Tiew
FKFanny Wai San Ko
Fanny Wai San Ko
SPSze Lei Pang
Sze Lei Pang
SMSri Anusha Matta
Sri Anusha Matta
YSYang Yie Sio
Yang Yie Sio
SCSanjay Haresh Chotirmall
Sanjay Haresh Chotirmall
Introduction: Allergic sensitisation to fungi such asAspergillusare associated to poor clinical outcomes in asthma, bronchiectasis and cystic fibrosis; however, clinical relevance in COPD remains unclear.Methods: Patients with stable COPD (n=446) and nondiseased controls (n=51) were prospectively recruited across three countries (Singapore, Malaysia and Hong Kong) and screened against a comprehensive allergen panel including house dust mites, pollens, cockroach and fungi. For the first time, using a metagenomics approach, we assessed outdoor and indoor environmental allergen exposure in COPD. We identified key fungi in outdoor air and developed specific-IgE assays against the top culturable fungi, linking sensitisation responses to COPD outcomes. Indoor air and surface allergens were prospectively evaluated by metagenomics in the homes of 11 COPD patients and linked to clinical outcome.Results: High frequencies of sensitisation to a broad range of allergens occur in COPD. Fungal sensitisation associates with frequent exacerbations, and unsupervised clustering reveals a “highly sensitised fungal predominant” subgroup demonstrating significant symptomatology, frequent exacerbations and poor lung function. Outdoor and indoor environments serve as important reservoirs of fungal allergen exposure in COPD and promote a sensitisation response to outdoor air fungi. Indoor (home) environments with high fungal allergens associate with greater COPD symptoms and poorer lung function, illustrating the importance of environmental exposures on clinical outcomes in COPD.Conclusion: Fungal sensitisation is prevalent in COPD and associates with frequent exacerbations representing a potential treatable trait. Outdoor and indoor (home) environments represent a key source of fungal allergen exposure, amenable to intervention, in “sensitised” COPD.

1 April 2019 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
MAMicheál Mac Aogáin
Micheál Mac Aogáin
PTPei Yee Tiew
Pei Yee Tiew
ALAlbert Yick Hou Lim
Albert Yick Hou Lim
TLTeck Boon Low
Teck Boon Low
GTGan Liang Tan
Gan Liang Tan
SCSanjay Haresh Chotirmall
Sanjay Haresh Chotirmall
Rationale: Allergic sensitization is associated with poor clinical outcomes in asthma, chronic obstructive pulmonary disease, and cystic fibrosis; however, its presence, frequency, and clinical significance in non–cystic fibrosis bronchiectasis remain unclear. Objectives: To determine the frequency and geographic variability that exists in a sensitization pattern to common and specific allergens, including house dust mite and fungi, and to correlate such patterns to airway immune-inflammatory status and clinical outcomes in bronchiectasis. Methods: Patients with bronchiectasis were recruited in Asia (Singapore and Malaysia) and the United Kingdom (Scotland) (n = 238), forming the Cohort of Asian and Matched European Bronchiectasis, which matched recruited patients on age, sex, and bronchiectasis severity. Specific IgE response against a range of common allergens was determined, combined with airway immune-inflammatory status and correlated to clinical outcomes. Clinically relevant patient clusters, based on sensitization pattern and airway immune profiles (“immunoallertypes”), were determined. Measurements and Main Results: A high frequency of sensitization to multiple allergens was detected in bronchiectasis, exceeding that in a comparator cohort with allergic rhinitis (n = 149). Sensitization was associated with poor clinical outcomes, including decreased pulmonary function and more severe disease. “Sensitized bronchiectasis” was classified into two immunoallertypes: one fungal driven and proinflammatory, the other house dust mite driven and chemokine dominant, with the former demonstrating poorer clinical outcome. Conclusions: Allergic sensitization occurs at high frequency in patients with bronchiectasis recruited from different global centers. Improving endophenotyping of sensitized bronchiectasis, a clinically significant state, and a “treatable trait” permits therapeutic intervention in appropriate patients, and may allow improved stratification in future bronchiectasis research and clinical trials.